Market Overview

Credit Suisse Believes Top Line Growth Matters More Than Margins For Stericycle

Related SRCL
Stericycle Prices Public Offering of Mandatory Convertible Preferred Stock at $100/Depositary Share
Stericycle to Acquire Shred-it International, Creating Global Leader in Business-to-Business Compliance Solutions

In a report published Monday, Credit Suisse analyst Hamzah Mazari reiterated an Outperform rating and $140.00 price target on Stericycle (NASDAQ: SRCL).

In the report, Credit Suisse noted, “We believe that operating leverage given lack of infrastructure pre-PSC deal should lead to much higher than expected earnings power over the next 12-16 months. Recall that SRCL can run StrongPak through PSC infrastructure and cut out third party treatment/disposal costs (i.e. had 1 Part B facility vs 13 post deal) in addition to better optimizing route density/logistics. Our sense is that 12 cents of 2015 full year EPS accretion is low based on our channel checks and past environmental deals.”

Stericycle closed on Thursday at $119.23.

Latest Ratings for SRCL

May 2015Stifel NicolausMaintainsBuy
Mar 2015Imperial CapitalInitiates Coverage onIn-line
Nov 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: Credit Suisse Hamzah MazariAnalyst Color Reiteration Analyst Ratings


Related Articles (SRCL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters